Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

3.7K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
3.7K
Tissue-Drug Binding: Localization of Drugs and its Significance01:24

Tissue-Drug Binding: Localization of Drugs and its Significance

598
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
598

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026
Same author

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

European urology·2026
Same author

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.

Cancer·2026
Same author

First-trimester preexisting diabetes screening in Medicaid beneficiaries.

Pregnancy (Hoboken, N.J.)·2026
Same author

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Socioeconomic and Demographic Factors in Genetic Testing Utilization Among Advanced Prostate Cancer Patients.

The Prostate·2026

Related Experiment Video

Updated: May 2, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.2K

Dose-Dense Docetaxel and Radium-223 in Bone-Dominant Metastatic Castration-Resistant Prostate Cancer.

Brendan Connell1, Clara Hwang2, Edmund Folefac3

  • 1Department of Hematology & Oncology, Tufts Medical Center, Boston, MA; Division of Hematology & Oncology, Lahey Hospital & Medical Center, Burlington, MA.

Clinical Genitourinary Cancer
|May 18, 2025
PubMed
Summary

Dose-dense docetaxel combined with radium-223 is a safe and effective treatment for bone-dominant castration-resistant prostate cancer. This combination showed promising progression-free and overall survival rates with manageable toxicity.

Keywords:
Bone metastasesCombination therapyEfficacyLead-in cycleSafety

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.1K

Related Experiment Videos

Last Updated: May 2, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.2K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.1K

Area of Science:

  • Oncology
  • Medical Oncology
  • Prostate Cancer Research

Background:

  • Castration-resistant prostate cancer (CRPC) often progresses with bone metastases.
  • Docetaxel and radium-223 are effective treatments, but myelosuppression limits their combination.
  • Dose-dense docetaxel regimens may mitigate myelosuppression.

Purpose of the Study:

  • To evaluate the safety and efficacy of combining dose-dense docetaxel with radium-223 in patients with bone-dominant metastatic CRPC.
  • To determine the maximum tolerated dose (MTD) of this combination therapy.

Main Methods:

  • A dose escalation and expansion study design was used.
  • Patients received a 4-week lead-in of dose-dense docetaxel (every 2 weeks), followed by combination with radium-223 every 4 weeks.
  • Dose levels of docetaxel were escalated, with granulocyte-colony stimulating factor (G-CSF) support, to determine the MTD.

Main Results:

  • The MTD was determined to be docetaxel 50 mg/m² with G-CSF on Day 16.
  • No febrile neutropenia events were observed in 35 patients treated at the MTD.
  • The combination demonstrated a PSA50 response rate of 51.4% and a PSA90 response rate of 25.7%.

Conclusions:

  • A dose-dense docetaxel schedule with G-CSF allows for safe combination with standard-dose radium-223.
  • This regimen shows potential for treating bone-dominant metastatic CRPC with manageable hematological toxicity.
  • The combination may be suitable for further study in high-risk, high-volume castration-sensitive metastatic disease.